Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review.

Pharmacogenomics - 1 Jan 2024

Bevers Lisanne A H, Jensen Rebecca L, Owen Andrew, Colbers Angela, Carr Daniel F, Burger David M

Abstract excerpt

BACKGROUND: Dolutegravir (DTG) is an antiviral agent used for the treatment of HIV, however, there is uncertainty over the influence of genetic variation on DTG exposure, and whether it has clinical implications for the efficacy or toxicity in different populations. This systematic review aims to create an overview of the impact of pharmacogenomics (PGx) on DTG exposure, efficacy, and toxicity. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to HIV Integrase Inhibitors

Share to Oxazines

Share to Pharmacogenetics

Share to Piperazines

Share to Pyridones

Source

Open in PubMed Open full text

Identifiers

PMID: 39697075
DOI: 10.1080/14622416.2024.2441104
PMCID: PMC11703464

Genes

ABCB1
ABCG2
NR1I2
SLC22A2
UGT1A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review.PMID 39697075Read ↗

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.Semantic proximity Read ↗

Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency VirusSemantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.Semantic proximity Read ↗

Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients.Semantic proximity Read ↗

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIVSemantic proximity Read ↗

UGT1A1 regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa.Semantic proximity Read ↗

Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Semantic proximity Read ↗

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysisSemantic proximity Read ↗

Pharmacogenetics of anti-HIV drugs.Semantic proximity Read ↗

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.Semantic proximity Read ↗

Pharmacogenomics of Antiretroviral Drug Metabolism and TransportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.